Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy

NCT04652570 | Terminated Phase 1 DMC FDA Drug

• 1 other identifier: 119-01-01
• Study Type: interventional
• Target: 6
• Locations: 1 country
• Sites: 4

Brief Summary

This study is a Phase 1b/2a, open-label, sequential-cohort, dose escalation, and dose expansion study to evaluate the safety, tolerability, PK, and PD of VB119 in subjects with primary MN

Conditions

Membranous Nephropathy

Outcome Measures

Primary Outcomes (2)

• Incidence of Treatment-Emergent Adverse Events

  Safety and Tolerability

  Through study completion, an average of 18 months

• Incidence of Clinical Laboratory Assessments

  Safety and Tolerability

  Through study completion, an average of 18 months

Secondary Outcomes (6)

• % of Patients with Anti-Drug Antibodies

  Through study completion, an average of 18 months

• Maximum Plasma Concentration [Cmax]

  Week 12

• Time to Maximum Plasma Concentration [Tmax]

  Week 12

• % of patients achieving complete remission of proteinuria

  Through study completion, an average of 18 months

• Anti-PLA2R Antibody Assessment

  Through study completion, an average of 18 months

Study Arms (1)

VB119 dose escalation

EXPERIMENTAL

Dose escalation phase followed by a dose expansion phase. VB119 to be administered as intravenous infusions.

Drug: VB119

Interventions

VB119 DRUG

Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.

VB119 dose escalation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Is ≥ 18 years of age at the time of informed consent;
• Has a kidney biopsy-proven diagnosis of primary MN within the past 10 years; Note: It is preferable that subjects enrolled have kidney biopsy tissue samples that are positive for anti-PLA2R antibody staining. Subjects with kidney biopsy-proven diagnosis of primary MN \>10 years and ≤20 years that meet all other eligibility criteria may be enrolled after discussion with the Medical Monitor.
• \. Has a documented laboratory history of nephrotic range proteinuria (defined as either greater than or equal to 3.5 g total protein per 24-hour urine collection or greater than or equal to 3.5 g/g UPCR by spot collection) AND has proteinuria with a UPCR greater than or equal to 2.0 g/g based on 2 consecutive spot urine (first morning void) sample collections obtained within 14 days of each other during the Screening Period. Both samples must qualify;
• Has systolic blood pressure (BP) \<160 mmHg or diastolic BP \<100 mmHg after 5 minutes of rest at Screening;
• Is willing and able to provide written informed consent prior to Screening;
• Female subjects of non-childbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before the Screening Visit) or postmenopausal, defined as spontaneous amenorrhea for at least 2 years, with follicle-stimulating hormone in the postmenopausal range at Screening, based on the central laboratory's ranges;
• Female subjects of childbearing potential (ie, ovulating, premenopausal, or not surgically sterile) and all male subjects must use a medically accepted, highly effective contraceptive regimen during their participation in the study and for 125 days after the last administration of study drug.
• Male subjects must agree to abstain from sperm donation through 125 days after administration of the last dose of study drug.

You may not qualify if:

• Has an eGFR \<45 mL/min/1.73 m2 at Screening utilizing the Chronic Kidney Disease Epidemiology Collaboration formula confirmed by the central laboratory;
• Has an absolute neutrophil count \<1.5 x 10/L;
• Has a white blood cell count \<3.0 x 10/L;
• Has secondary causes of MN (eg, malignancy, hepatitis B or C, human immunodeficiency virus \[HIV\], systemic lupus erythematosus \[SLE\], or other autoimmune diseases \[eg, thyroiditis\], drug-induced);
• Has a diagnosis or history of SLE (including non renal disease);
• Has type 1 or 2 diabetes mellitus;
• Has an acute, chronic, or latent infection, including tuberculosis, hepatitis, HIV, or chronic urinary tract infections;

Sponsors & Collaborators

• Tenet Medicines: lead

Study Sites (4)

Clinical Reserach Site

Los Angeles, California, 91324, United States

Location

Clinical Research Site

Albany, New York, 12209, United States

Location

Clinical Research Site

Bethlehem, Pennsylvania, 18017, United States

Location

Clinical Research Site

Dallas, Texas, 75208, United States

Location

MeSH Terms

Conditions

Glomerulonephritis, Membranous

Condition Hierarchy (Ancestors)

Glomerulonephritis; Nephritis; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Keenan

  ValenzaBio, Inc.

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 23, 2020
• First Posted: December 3, 2020
• Study Start: May 5, 2021
• Primary Completion: November 21, 2023
• Study Completion: August 15, 2024
• Last Updated: February 12, 2026

Record last verified: 2026-02

Locations

US (4)